help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakashiro, K.-i.
Right arrow Articles by Oyasu, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakashiro, K.-i.
Right arrow Articles by Oyasu, R.
(American Journal of Pathology. 2001;159:591-597.)
© 2001 American Society for Investigative Pathology

Regular Articles

Role of Peroxisome Proliferator-Activated Receptor {gamma} and Its Ligands in Non-Neoplastic and Neoplastic Human Urothelial Cells

Koh-ichi Nakashiro, Yoshiki Hayashi, Akiyo Kita, Tetsuya Tamatani, Alexandre Chlenski, Nobuteru Usuda, Kazunori Hattori, Janardan K. Reddy and Ryoichi Oyasu

From the Department of Pathology, Northwestern University Medical School, Chicago, Illinois

Peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) is a member of the nuclear receptor superfamily of ligand-activated transcription factors and is expressed in several types of tissue. Although PPAR{gamma} reportedly is expressed in normal urothelium, its function is unknown. We examined the expression of PPAR{gamma} in normal urothelium and bladder cancer in an attempt to assess its functional role. Immunohistochemical staining revealed normal urothelium to express PPAR{gamma} uniformly. All low-grade carcinomas were positive either diffusely or focally, whereas staining was primarily focal or absent in high-grade carcinomas. A nonneoplastic urothelial cell line (1T-1), a low-grade (RT4) carcinoma cell line, and two high-grade (T24 and 253J) carcinoma cell lines in culture expressed PPAR{gamma} mRNA and protein. Luciferase assay indicated that PPAR{gamma} was functional. PPAR{gamma} ligands (15-deoxy-{Delta}12,14-prostaglandin J2, troglitazone and pioglitazone) suppressed the growth of nonneoplastic and neoplastic urothelial cells in a dose-dependent manner. However, neoplastic cells were more resistant than were nonneoplastic cells. Failure to express PPAR{gamma} or ineffective transcriptional activity may be some of the mechanisms responsible for resistance to the inhibitory action of PPAR{gamma} ligands.




This article has been cited by other articles:


Home page
 Toxicol PatholHome page
G. G. Long, V. L. Reynolds, L. W. Dochterman, and T. E. Ryan
Neoplastic and Non-neoplastic Changes in F-344 Rats Treated with Naveglitazar, a {gamma}-Dominant PPAR {alpha}/{gamma} Agonist
Toxicol Pathol, October 1, 2009; 37(6): 741 - 753.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
G. G. Long, V. L. Reynolds, A. Lopez-Martinez, T. E. Ryan, S. L. White, and S. R. Eldridge
Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a {gamma}-dominant PPAR {alpha}/{gamma} Agonist: Lack of Evidence for Urolithiasis as an Inciting Event
Toxicol Pathol, February 1, 2008; 36(2): 218 - 231.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
M. A. Dominick, M. R. White, T. P. Sanderson, T. van Vleet, S. M. Cohen, L. E. Arnold, M. Cano, S. Tannehill-Gregg, J. D. Moehlenkamp, C. R. Waites, et al.
Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPAR{alpha}/{gamma} Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of Action
Toxicol Pathol, December 1, 2006; 34(7): 903 - 920.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Ota, K. Ito, T. Suzuki, S. Saito, M. Tamura, S.-i. Hayashi, K. Okamura, H. Sasano, and N. Yaegashi
Peroxisome Proliferator-Activated Receptor {gamma} and Growth Inhibition by Its Ligands in Uterine Endometrial Carcinoma.
Clin. Cancer Res., July 15, 2006; 12(14): 4200 - 4208.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Kassouf, S. Chintharlapalli, M. Abdelrahim, G. Nelkin, S. Safe, and A. M. Kamat
Inhibition of Bladder Tumor Growth by 1,1-Bis(3'-Indolyl)-1-(p-Substitutedphenyl)Methanes: A New Class of Peroxisome Proliferator-Activated Receptor {gamma} Agonists
Cancer Res., January 1, 2006; 66(1): 412 - 418.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
G. Ohlsson, J. M. A. Moreira, P. Gromov, G. Sauter, and J. E. Celis
Loss of Expression of the Adipocyte-type Fatty Acid-binding Protein (A-FABP) Is Associated with Progression of Human Urothelial Carcinomas
Mol. Cell. Proteomics, April 1, 2005; 4(4): 570 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. L. Varley, J. Stahlschmidt, B. Smith, M. Stower, and J. Southgate
Activation of Peroxisome Proliferator-Activated Receptor-{gamma} Reverses Squamous Metaplasia and Induces Transitional Differentiation in Normal Human Urothelial Cells
Am. J. Pathol., May 1, 2004; 164(5): 1789 - 1798.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
C. L. Varley, J. Stahlschmidt, W.-C. Lee, J. Holder, C. Diggle, P. J. Selby, L. K. Trejdosiewicz, and J. Southgate
Role of PPAR {gamma} and EGFR signalling in the urothelial terminal differentiation programme
J. Cell Sci., April 15, 2004; 117(10): 2029 - 2036.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
W K Leung, A H C Bai, V Y W Chan, J Yu, M W Y Chan, K-F To, J-R Wu, K-K Chan, Y-G Fu, F K L Chan, et al.
Effect of peroxisome proliferator activated receptor {gamma} ligands on growth and gene expression profiles of gastric cancer cells
Gut, March 1, 2004; 53(3): 331 - 338.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Society for Investigative Pathology.